SUBSCRIBE
SUBSCRIBE

Phase III

Drug Development
Biopharma Update on the Novel Coronavirus: April 13
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
April 13, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: April 6-10
It was a very busy week for clinical trial news. Here’s a look.
April 10, 2020
 · 
12 min read
 · 
Mark Terry
Physician holds up hand in a stop sign signal_Shut
Drug Development
COVID-19 Continues to Impact Enrollment and Recruitment of Clinical Trial Patients
As COVID-19 has swept across the world, companies have had to make significant adjustments to the way business is conducted in a global economy. It has impacted all types of operations, including clinical trials.
April 10, 2020
 · 
4 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: April 10
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 10, 2020.
April 10, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: April 9
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 9, 2020.
April 9, 2020
 · 
9 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 8
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.
April 8, 2020
 · 
7 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: April 7
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
April 7, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Drug Development
Immunomedics’ Triple-Negative Breast Cancer Trial Halted Early Due to Compelling Efficacy
“Today’s announcement marks a significant milestone towards fulfilling our promise to patients globally with TNBC of providing a new treatment option that can meaningfully improve their lives,” said Behzad Aghazadeh, executive chairman of Immunomedics.
April 6, 2020
 · 
2 min read
 · 
Mark Terry
Photo of Incyte logo/Eyesonmilan via Getty Images
Drug Development
Incyte’s Ruxolitinib Shows Significant Improvement in Atopic Dermatitis Trials
The research was presented at the Revolutionizing Atopic Dermatitis Virtual Symposium.
April 6, 2020
 · 
3 min read
 · 
Mark Terry
Dupixant gets positive results for treating Prurig
Drug Development
Menlo’s Serlopitant for Prurigo Nodularis Itching Flunks Two Phase III Trials
Menlo Therapeutics released topline results from two Phase III trials of once daily oral serlopitant for pruritus (itching) associated with prurigo nodularis. Neither trial met their primary endpoint.
April 6, 2020
 · 
3 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Press Releases
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
January 23, 2026
 · 
17 min read
Press Releases
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
January 23, 2026
 · 
7 min read
Press Releases
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
January 22, 2026
 · 
17 min read
Press Releases
IntraBio Announces Positive Pivotal Trial Results of Levacetylleucine for the Treatment of Ataxia-Telangiectasia
January 21, 2026
 · 
5 min read
Press Releases
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS)
January 21, 2026
 · 
7 min read
Press Releases
FDA Granted Hopstem’s hNPC01 for Chronic Ischemic Stroke Approval to Enter Phase 2/3 Adaptive Pivotal Clinical Trial with Bridging Study
January 21, 2026
 · 
5 min read
Press Releases
Tanabe Pharma America Announces Positive Topline Results for Dersimelagon in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
January 21, 2026
 · 
5 min read
Press Releases
SpyGlass Pharma Announces First Patients Randomized in SGP-005 and SGP-006, Two Registrational Phase III Clinical Trials of Its Novel BIM-IOL System
January 20, 2026
 · 
5 min read
Press Releases
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
January 19, 2026
 · 
7 min read
Press Releases
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
13 min read
Press Releases
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
January 19, 2026
 · 
13 min read
Press Releases
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 19, 2026
 · 
9 min read
Press Releases
New clinical data highlights CAPLYTA® (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
January 19, 2026
 · 
17 min read
Press Releases
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
January 16, 2026
 · 
6 min read
Press Releases
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
January 16, 2026
 · 
7 min read
Press Releases
TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
January 15, 2026
 · 
34 min read
Press Releases
Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly’s Olumiant®
January 15, 2026
 · 
5 min read
Press Releases
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
January 14, 2026
 · 
13 min read
Press Releases
ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer
January 14, 2026
 · 
9 min read
Press Releases
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2
January 14, 2026
 · 
4 min read
Load More